**
In a significant development amidst the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC), health authorities have launched a groundbreaking treatment trial just six weeks after the World Health Organization (WHO) declared the situation a public health emergency. The initiative aims to evaluate two promising drugs that could potentially lower mortality rates associated with the Bundibugyo strain of the virus, which has already claimed 625 lives among 1,792 confirmed cases as of July 9.
Urgency of the Situation
In Bunia, the capital of Ituri province, the local community is feeling the urgency of the outbreak. Neema Haba, a local banana seller and mother of three, expressed her desperation, stating, “I hope these drug trials proceed quickly. Financially, we are being driven to the brink by this outbreak, and nothing is going right.” The outbreak continues to unfold; it has been classified by the WHO as still in an “expansion phase,” further complicating the response efforts.
The outbreak’s intensity highlights the reliance on traditional public health measures—case identification, isolation, and contact tracing. However, the lack of trust in authorities and the mobility of the population have hampered these efforts. Local frontline workers have also faced challenges, including protests over unpaid wages. One worker, Ovide Maliabo, shared the risks involved, adding, “At one point, we narrowly escaped being lynched.” This illustrates the precarious situation for those attempting to manage the outbreak under dire circumstances.
The Treatment Trial
The newly initiated Partners treatment trial involves two experimental drugs: remdesivir, an antiviral produced by Gilead Sciences, and MBP134, a monoclonal antibody developed by Mapp Biopharmaceutical. Patients enrolled in the trial will be randomly assigned to receive one of these drugs, a combination of both, or standard supportive care.
Prof. Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp highlighted the potential these drugs have shown in animal models, stating, “These two drugs actually have been proven to work against the Bundibugyo virus in animal models. They showed great efficacy, but now we need to test it in humans.” While Bundibugyo typically has a lower mortality rate compared to the Zaire strain, it still presents a significant threat, killing about one-third of those infected.
As the trial progresses, researchers are keenly observing the outcomes between those receiving experimental treatments and those on standard care. “Any improvement is good,” Liesenborghs remarked, emphasizing the need for statistically significant results.
Community Challenges and Support
The response to the outbreak is complicated by logistical challenges, including shortages of personal protective equipment and transport for deceased patients. Local authorities have faced criticism for insufficient payment to frontline workers, which has resulted in strikes that further impede response efforts. The closure of Bunia’s airport has compounded logistical issues, affecting the supply of essential resources to combat the virus.
Despite these challenges, the trial has garnered support from international health organisations, with enough supplies of remdesivir and MBP134 for approximately 1,200 patients. The trial design is adaptable, allowing for the incorporation of additional treatments as they become available. Importantly, the trial is open to patients of all ages, including pregnant and breastfeeding women, who are often excluded from medical research.
Hope for the Future
The speed at which this trial has been organised is commendable. Prof. Amanda Rojek, an international principal investigator for the Partners trial, noted, “It’s just fantastic we’ve managed to get started so quickly.” This contrasts sharply with the protracted timelines of previous outbreaks, such as the one in West Africa from 2014-2016, where it took over a year to initiate clinical trials.
The ongoing efforts to provide effective treatments not only aim to save lives but also to restore trust within the community. Prof. Yap Boum, head of emergency response at the Africa CDC, emphasised that effective care and treatment could indeed change public perception of health authorities. “These trials will enable us to access treatment, and when we treat people, it also sends a message to the community,” he explained.
Why it Matters
The swift initiation of this treatment trial in the DRC is a crucial step in the global fight against Ebola, particularly at a time when the disease poses a severe threat to public health. By potentially providing effective therapies, the trial not only has the capacity to reduce mortality rates but also plays a pivotal role in rebuilding trust between health authorities and local communities. As the world watches, the outcomes of these trials could reshape future responses to Ebola outbreaks and inform strategies for tackling similar infectious diseases globally.
